London, City of London / Syndication Cloud / January 24, 2026 / HITO Holistic Health Temporomandibular joint disorders ...
Most US adults did not know about nonstatin medications and were not aware of lipoprotein(a) or coronary artery calcium scores.
Vunakizumab significantly improved clinical responses in active psoriatic arthritis in a phase 2 trial. Read more about the study.
Vunakizumab, an interleukin-17 inhibitor, shows improved efficacy over placebo in treating active psoriatic arthritis at week 12, with mild or moderate treatment-emergent adverse events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results